Art of TIL immunotherapy: SITC's perspective on demystifying a complex treatment.

ABSTRACT: In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved for patients with disease refractory to immune checkpoint inhibitors. Since the advent of chimeric antigen receptor (CAR) T cells for patients with hematological malignancies, a growing network of centers capable of delivering effector T cell products to patients has developed. Administration of TIL can be layered onto that institutional framework, but there are many complex and unique aspects to TIL immunotherapy. The highly multidisciplinary clinical expertise and coordination required to suc

SUBMITTER: Turcotte S 

PROVIDER: S-EPMC11752064 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature